Clinical trial
A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
NCT00193297 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
- Lead sponsor
- SCRI Development Innovations, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2002
- Completion date
- June 30, 2006
- Enrollment
- 50
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
ovary cancer